Bristol Myers Squibb Price to Book Ratio 2010-2023 | BMY
Historical price to book ratio values for Bristol Myers Squibb (BMY) over the last 10 years. The current price to book ratio for Bristol Myers Squibb as of June 02, 2023 is 4.33.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Bristol Myers Squibb Price/Book Ratio Historical Data |
| Date |
Stock Price |
Book Value per Share |
Price to Book Ratio |
| 2023-06-02 |
65.66 |
|
4.32 |
| 2023-03-31 |
68.76 |
$15.18 |
4.53 |
| 2022-12-31 |
70.81 |
$14.83 |
4.77 |
| 2022-09-30 |
69.43 |
$15.41 |
4.51 |
| 2022-06-30 |
75.21 |
$15.30 |
4.92 |
| 2022-03-31 |
70.83 |
$14.86 |
4.77 |
| 2021-12-31 |
59.51 |
$16.55 |
3.60 |
| 2021-09-30 |
56.47 |
$16.79 |
3.36 |
| 2021-06-30 |
62.79 |
$16.60 |
3.78 |
| 2021-03-31 |
59.32 |
$16.89 |
3.51 |
| 2020-12-31 |
57.84 |
$17.06 |
3.39 |
| 2020-09-30 |
55.36 |
$22.23 |
2.49 |
| 2020-06-30 |
53.58 |
$21.81 |
2.46 |
| 2020-03-31 |
50.38 |
$22.08 |
2.28 |
| 2019-12-31 |
57.61 |
$23.20 |
2.48 |
| 2019-09-30 |
45.14 |
$10.90 |
4.14 |
| 2019-06-30 |
40.02 |
$9.87 |
4.05 |
| 2019-03-31 |
41.73 |
$9.36 |
4.46 |
| 2018-12-31 |
45.06 |
$8.70 |
5.18 |
| 2018-09-30 |
53.47 |
$8.43 |
6.35 |
| 2018-06-30 |
47.33 |
$7.61 |
6.22 |
| 2018-03-31 |
53.74 |
$7.90 |
6.80 |
| 2017-12-31 |
51.74 |
$7.29 |
7.10 |
| 2017-09-30 |
53.49 |
$9.11 |
5.87 |
| 2017-06-30 |
46.43 |
$9.04 |
5.14 |
| 2017-03-31 |
44.99 |
$8.83 |
5.10 |
| 2016-12-31 |
48.03 |
$9.82 |
4.89 |
| 2016-09-30 |
44.01 |
$9.49 |
4.64 |
| 2016-06-30 |
60.03 |
$9.07 |
6.62 |
| 2016-03-31 |
51.87 |
$8.76 |
5.92 |
| 2015-12-31 |
55.52 |
$8.68 |
6.39 |
| 2015-09-30 |
47.52 |
$9.20 |
5.17 |
| 2015-06-30 |
52.79 |
$9.22 |
5.73 |
| 2015-03-31 |
50.88 |
$9.46 |
5.38 |
| 2014-12-31 |
46.56 |
$9.06 |
5.14 |
| 2014-09-30 |
39.84 |
$9.21 |
4.33 |
| 2014-06-30 |
37.48 |
$9.32 |
4.02 |
| 2014-03-31 |
39.86 |
$9.42 |
4.23 |
| 2013-12-31 |
40.78 |
$9.28 |
4.39 |
| 2013-09-30 |
35.01 |
$8.98 |
3.90 |
| 2013-06-30 |
33.54 |
$8.77 |
3.82 |
| 2013-03-31 |
30.65 |
$8.38 |
3.66 |
| 2012-12-31 |
24.00 |
$8.37 |
2.87 |
| 2012-09-30 |
24.60 |
$8.47 |
2.91 |
| 2012-06-30 |
25.95 |
$9.47 |
2.74 |
| 2012-03-31 |
24.12 |
$9.65 |
2.50 |
| 2011-12-31 |
24.94 |
$9.42 |
2.65 |
| 2011-09-30 |
21.98 |
$9.73 |
2.26 |
| 2011-06-30 |
20.29 |
$9.50 |
2.14 |
| 2011-03-31 |
18.30 |
$9.35 |
1.96 |
| 2010-12-31 |
17.89 |
$9.20 |
1.94 |
| 2010-09-30 |
18.31 |
$9.29 |
1.97 |
| 2010-06-30 |
16.65 |
$9.11 |
1.83 |
| 2010-03-31 |
17.60 |
$8.88 |
1.98 |
| 2009-12-31 |
16.45 |
$8.65 |
1.90 |
| 2009-09-30 |
14.49 |
$7.27 |
1.99 |
| 2009-06-30 |
12.70 |
$7.05 |
1.80 |
| 2009-03-31 |
13.51 |
$6.64 |
2.03 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$137.942B |
$46.159B |
|
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
|
